Skip to main content
GMAB
NASDAQ Life Sciences

Genmab 9M Revenue Up 22% to $3,238M; Net Profit Falls to $698M on Merus Costs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$54.17
Mkt Cap
$32.034B
52W Low
$23.62
52W High
$59.97
52W Position info
129% above low
Off High info
9.7% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

GMAB has more than doubled off its 52-week low of $23.62 on light trading volume (0.4× avg).

Summary

Genmab's nine-month revenue rose 22% to $3,238 million on DARZALEX and EPKINLY strength, but net profit fell to $698 million as Merus integration costs and $324 million of acquisition-debt interest weighed. Full-year guidance was maintained.


Key Events · Earnings and Guidance · GMAB

  • Nine-Month Revenue Up 22%

    Revenue reached $3,238 million for the first nine months of 2026 versus $2,662 million a year earlier, a $576 million increase driven by DARZALEX and Kesimpta royalties and higher EPKINLY net product sales.

  • Net Profit Falls on Costs and Debt

    Net profit was $698 million versus $932 million, as operating expenses rose 35% to $2,018 million and financial items swung to a $263 million net expense, including $256 million of interest and $68 million of fee amortization on the Merus acquisition borrowings.

  • EPKINLY Sales Up 47%

    Global EPKINLY/TEPKINLY net sales were $491 million versus $333 million, with U.S. and Japan net product sales recorded by Genmab of $381 million; DARZALEX royalties contributed $2,057 million on J&J net sales of $12,410 million.

  • 2026 Guidance Maintained

    Genmab reiterated guidance first published August 6, 2026: revenue of $4.325-4.525 billion and adjusted operating profit of $1.065-1.385 billion, with adjusted operating expenses of $2.81-2.95 billion.


Analysis · GMAB · Life Sciences

Revenue growth is real and broad-based, with DARZALEX royalties of $2,057 million and EPKINLY net sales up 47%. The bottom line went the other way: net profit dropped to $698 million from $932 million as operating expenses rose 35% to $2,018 million and $324 million of interest and fee amortization on the Merus acquisition debt hit financial items. Guidance was held, so the quarter is a cost-and-leverage story rather than a demand story. The bigger swing factor sits outside this report: October's positive Phase 3 readouts for epcoritamab, Rina-S and petosemtamab set up regulatory submissions and potential 2027 launches, and the spend ramp here is the price of that launch build-out.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GMAB was trading at $54.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32B. The 52-week trading range was $23.62 to $59.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GMAB - Latest Insights

GMAB
Oct 28, 2026, 9:41 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.12
Real-time Price: $51.30 info
Change: +$6.18 (+14%) info
Market Cap: $30.674B info
GMAB
Oct 26, 2026, 11:08 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $44.35
Real-time Price: $51.30 info
Change: +$6.95 (+16%) info
Market Cap: $30.674B info
GMAB
Oct 26, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $51.30 info
Change: +$5.95 (+13%) info
Market Cap: $30.674B info
GMAB
Oct 23, 2026, 11:56 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $40.64
Real-time Price: $51.30 info
Change: +$10.66 (+26%) info
Market Cap: $30.674B info
GMAB
Oct 13, 2026, 6:22 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $37.66
Real-time Price: $51.30 info
Change: +$13.64 (+36%) info
Market Cap: $30.674B info